Renal Pelvis and Ureter Carcinoma — Variants & evidence

Renal Pelvis and Ureter Carcinoma — Variants & evidence · CancerIndex

Variants & evidence

Curated clinical evidence by variant and therapy

3 evidence items mapped to this entity or its descendants, grouped by molecular profile, then therapy. 50 items per page.

civicCuratedShowing 1–3 of 3 evidence items (3 on this page mapped to a descendant entity) · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
FGFR3 S249C1
AZD-4547	Renal Pelvis Urothelial CarcinomaALIAS	Predictive	C	Supports Sensitivity Response	1	submitted	EID8316 The phase II NCI-MATCH trial (EAY131) subprotocol W assessed the FGFR1-3 selective TKI AZD-4547 in 48 patients with FGFR1/2 amplifications, FGFR2/3 SNV or FGFR1/3 fusions. The partial response overall… (full text at CIViC) PMID 32463741 · Chae et al., 2020 · Open in CIViC	civic
TACC3 Fusion1
Fexagratinib	Renal Pelvis Urothelial CarcinomaALIAS	Predictive	C	Supports Sensitivity Response	1	submitted	EID9227 Phase II study (NCT02465060) from NCI-MATCH Trial (EAY131) Subprotocol W addressed the use of AZD4547 (an FGFR 1-3 inhibitor) in 48 tumor patients carrying FGFR 1-3 variants. Partial responses were ob… (full text at CIViC) PMID 32463741 · Chae et al., 2020 · Open in CIViC	civic
RAD50 L1237F1
Checkpoint Kinase Inhibitor AZD7762 + IrinotecanCombination	Ureter Small Cell Neuroendocrine CarcinomaALIAS	Predictive	C	Supports Sensitivity Response	4	accepted	EID5829 A 51-year-old woman with an invasive small-cell cancer of the ureter showed a durable complete response at 3-years when treated with AZD7762 (an ATP-competitive checkpoint kinase inhibitor) and irinot… (full text at CIViC) PMID 24934408 · Al-Ahmadie et al., 2014 · Open in CIViC	civic

Data updated 21 hours agoSource updated unknownsource: civic (CC0)

Evidence levels, directions and ratings are those assigned by CIViC curators. "Submitted" items have not completed curation review. This is not treatment guidance.